Clinical trial readout dates for Dianthus Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
| Phase 2 Claseprubart Multifocal Motor Neuropathy · NCT06537999 | December 2026 Ongoing |
| Phase 3 Claseprubart Myasthenia Gravis, Generalized · NCT07647510 | December 2028 Recruiting |
| Phase 3 Claseprubart Chronic Inflammatory Demyelinating Polyneuropathy · NCT06858579 | December 2028 Recruiting |
Dianthus Therapeutics Inc. reported $1.24B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $47M; at that rate the cash would last about 27 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-04 |